ISTX
PharmaISTX is a pharmaceutical company focused on Infectious Disease, Dermatology. Key products include ZEVTERA.
FDA Novel Drug Designations
(2024)See 1 novel approval →
ISTX's Key Drugs
ISTX's core commercial portfolio centers on ZEVTERA, spanning Infectious Disease and Dermatology — its most strategically important drugs approved in the last 15 years.
ISTX's Recent FDA Approvals
New NDA/BLA approvals for ISTX over the last two years — novel drugs only, excluding generics and label supplements.
ISTX's Therapeutic Areas
ISTX's approved drugs and pipeline span 2 therapeutic areas, led by Infectious Disease and Dermatology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ISTX's Top Competitors
ISTX's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Baxter, and B BRAUN. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
ISTX Pipeline Snapshot
Active clinical trials for ISTX across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • ZEVTERA leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Infectious Disease pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2024-04-03
- Latest
- 2024-04-03
- Applications
- 1